Decitabine regulates the resistance of HCC to sorafenib through demethylation

Decitabine regulates the resistance of HCC to sorafenib through demethylation

Abstract Purpose To evaluate the efficacy of sorafenib in combination with the DNA methylation inhibitor decitabine (DAC) for the treatment of hepatocellular carcinoma (HCC), and to investigate the mechanism of sorafenib resistance from an epigenetic perspective, aiming to provide new insights and s...

Full description

Saved in:

Bibliographic Details
Main Authors:	Miao Zhang, Xiaolei Zhou, Zhenzhen Li, TianYu Zhao, Yu Miao, Sen Liu, Qiaoqiao Han, Libo Wang, Yongdeng Xu, Tao Cui, Ze Wang, Xiulin Yi, Fengying Yan, Xiaoliang Wang
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Series:	Clinical Epigenetics
Subjects:	DNA methylation Decitabine Sorafenib OATP1B3 Hepatocellular carcinoma
Online Access:	https://doi.org/10.1186/s13148-025-01925-w
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mechanism of action of decitabine in treating acute lymphoblastic leukemia
by: Xiaohui Gao, et al.
Published: (2025-07-01)

Enhanced FOXO1 expression as a predictor of decitabine response and prolonged survival in high-risk myelodysplastic syndrome
by: Hong Liu, et al.
Published: (2025-12-01)

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trialResearch in context
by: Qifa Liu, et al.
Published: (2025-08-01)

HPLC-UV method development and validation for anticancer drug sorafenib and the co-prescribed drug dexamethasone: application to pharmacokinetic evaluation of sorafenib nanoformulations
by: Abdul Mateen, et al.
Published: (2025-04-01)

Sorafenib-Induced Spiny Follicular Hyperkeratosis: A Case Report with Review of Literature
by: Chandana Shajil, et al.
Published: (2024-04-01)

Approaches to conducting a physiologically relevant test (PRT) in the study of medicines containing substance IIc of the BCS subclass using sorafenib as an example
by: A. V. Suvorova, et al.
Published: (2024-09-01)

Decoding Drug Interactions: Character and Degree of Pharmacokinetic Interactions Between Telmisartan and Sorafenib or Donafenib in Rats
by: Li Y, et al.
Published: (2025-07-01)

Sorafenib tosylate inhibits autophagy, proliferation and migration of oral squamous cell carcinoma
by: XIONG Jianzhe, et al.
Published: (2024-08-01)

Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma
by: Eiji Higaki, et al.
Published: (2020-06-01)

Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis
by: Fanli Yuan, et al.
Published: (2025-08-01)

Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1
by: Jiali Zhao, et al.
Published: (2023-12-01)

Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-year Follow-up with Successful Sorafenib Treatment
by: Sirmen Kızılcan Çetin, et al.
Published: (2025-09-01)

Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation
by: Qiong Zhou, et al.
Published: (2025-07-01)

Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity
by: Lu M, et al.
Published: (2025-07-01)

Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients
by: Eman M. F. Barakat, et al.
Published: (2025-06-01)

The Effect of Radixin on the Function and Expression of Organic Anion Transporting Polypeptide 1B1
by: Chunxu Ni, et al.
Published: (2025-06-01)

Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation
by: Chunxiao Li, et al.
Published: (2025-01-01)

THE USE OF SORAFENIB (NEXAVAR) IN TREATMENT OF PATIENT WITH DISSEMINATED PARATHYROID CANCER: A CASE REPORT
by: V. A. Gorbunova, et al.
Published: (2017-04-01)

Prevalence of OATP1B‐Mediated Drug–Drug Interactions in an Academic Medical Center
by: Mathilde Bories, et al.
Published: (2025-06-01)

In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study
by: Wenyu Du, et al.
Published: (2025-07-01)

Endogenous protein S100A14 stabilizes glutaminase to render hepatocellular carcinoma resistant to sorafenib
by: Menghui Wang, et al.
Published: (2025-04-01)

Identifying genes associated with Sorafenib resistance in hepatocellular carcinoma to develop risk model
by: Kuan He, et al.
Published: (2025-08-01)

Inhibition of DNA methylation promotes breast tumor sensitivity to netrin‐1 interference
by: Mélodie Grandin, et al.
Published: (2016-07-01)

The Radiosensitizing Effect of Tumor-Derived Microparticles Co-Loaded with Sorafenib and Gold Nanoparticles on Hepatocellular Carcinoma
by: Yu L, et al.
Published: (2025-04-01)

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma
by: H. Freudenstein, et al.
Published: (2025-08-01)

Comparative analysis of bevacizumab and sorafenib on the survival of retinal ganglion cells in the treatment of retinal diseases
by: Wungrak Choi, et al.
Published: (2025-08-01)

ATF7IP inhibits Sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein
by: Yijie Su, et al.
Published: (2025-09-01)

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis
by: Maryam Hejazi, et al.
Published: (2025-08-01)

LOW DOSE CYTARABINE PLUS SORAFENIB IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA
by: Tural Mahmudov
Published: (2025-07-01)

Niosome as a Drug Delivery Carrier for Sorafenib: Preparation, Investigation of Physicochemical Properties, and In Vitro Effects on HepG2 Cell Line
by: Mohammad Amin Raeisi Estabragh, et al.
Published: (2024-12-01)

PENGARUH PEMBERIAN EKSTRAK DAUN SIRSAK TERHADAP DERAJAT HISTOPATOLOGI PADA TIKUS WISTAR KARSINOMA HEPATOSELULER YANG MENDAPAT TERAPI STANDAR SORAFENIB
by: Nanda Putri Mardiana Sinaga, et al.
Published: (2019-10-01)

Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis
by: Xu Li, et al.
Published: (2024-09-01)

Mechanisms of sorafenib-induced cardiotoxicity: ER stress induces upregulation of ATF3, leading to downregulation of NDUFS1 expression and mitochondrial dysfunction
by: Ming Yan, et al.
Published: (2025-08-01)

CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
by: P. A. Isaev, et al.
Published: (2015-04-01)

Multi-Organ Adverse Reaction to Two Hypomethylating Agents: A Challenge in High-Risk Myelodysplastic Syndrome Treatment
by: Sofia Brites Alves, et al.
Published: (2025-05-01)

PE-003 Assistência farmacêutica e farmacoeconomia no uso de sorafenibe em um CACON de Belém, PA: estratégias para otimização da terapia e melhoria da qualidade de vida
by: Márcia Moraes Paulino da Silva, et al.
Published: (2025-03-01)

Matrix stiffness-dependent PD-L2 deficiency improves SMYD3/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC
by: Shunxi Wang, et al.
Published: (2025-07-01)

PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma
by: Mengzhou Guo, et al.
Published: (2025-08-01)

SMYD2 epigenetically activates BMP4/SMAD1/5/8/ID3 axis to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma
by: Shanshan Wang, et al.
Published: (2025-09-01)

PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS
by: M. Y. Frolov, et al.
Published: (2016-09-01)